Parenteral nutrition (PN) is a life-sustaining therapy providing nutrients to individuals with impaired intestinal tract function and enteral access challenges. It is one of the most complex prescriptions written routinely in the hospital and home care settings. This article is to aid the nutrition support clinician in the safe provision of PN, including selecting appropriate patients for PN, vascular access, development of a PN admixture, appropriate therapy monitoring, recognition of preparation options, and awareness of preparation and stability concerns. (Nutr Clin Pract. 2016;31:578-595) 
Invited Review
Nutrition support of the adult patient with parenteral nutrition (PN) has advanced dramatically since its development and clinical introduction over 50 years ago. 1 A complex therapy with nearly 40 different components, PN requires careful patient selection, timing of initiation, individualized therapeutic dosing, and appropriate monitoring to maximize therapy benefits and minimize risks. 2 Furthermore, ordering practices vary between institutions and patient types (eg, neonate, pediatric, adult). Recent PN guidelines highlight education as an opportunity to improve safety and efficacy of PN. 3 Individuals involved in prescribing and monitoring PN should be confident in their knowledge of PN, including indications, vascular access, admixture design and delivery, and PN-associated complications. 2, 3 This article is intended to provide an overview of PN admixtures, including implementation and management strategies to assist the nutrition support clinician with safe and effective use of PN in the adult patient. While key to safe PN utilization, neither PN order entry nor PN review and verification processes will be covered in this article. The reader is directed to the American Society for Parenteral and Enteral Nutrition (ASPEN) PN resources page available at www.nutritioncare.org for additional information.
Indications
PN is traditionally indicated when an individual cannot be fed enterally. However, there are circumstances when infusion of nutrition intravenously may be more appropriate or required to provide adequate nutrients. The decision to initiate PN and the timing of initiation is often multifactorial and requires incorporation of elements such as the patient's desires, attitude toward the therapy, overall prognosis, nutrition status, and subjective quality of life. Incorporation of this information should provide clarity as to the purpose and goals of therapy. Patient desires, prognosis, and subjective quality of life often change with treatment duration and course of disease. Therefore, the indication for PN should be periodically reassessed.
Vascular Access
PN as well as other intravenous (IV) medications influence vascular access-type selection. Other factors to consider include expected duration of therapy, frequency of therapy (daily vs intermittent), patient activity level and lifestyle, surgical history of the head and neck, psychosocial issues, and ability to care for the device. 4 Prior to initiation of PN, it is important to evaluate a patient's vascular access type, tip location, and insertion site to ensure safe delivery of the preparation. Table 1 describes common IV access used for infusions of PN admixtures and briefly discusses advantages and disadvantages as well as limitations to each device. 
Formula Design

Assessing Energy and Protein Requirements
Components used in PN typically include protein as amino acids (AAs) and energy substrates as carbohydrates and fat, as well as electrolytes, vitamins, trace elements, minerals, and water. Careful consideration of patient-specific needs, including age, body habitus, nutrient requirements to support physical activity and maintain a healthy body mass index (BMI), and conditionspecific concerns (wounds, infection, critical illness, and kidney or liver dysfunction), needs to be incorporated into determining energy and protein requirements. [5] [6] [7] The most accurate way to predict metabolic needs is through indirect calorimetry, but use is limited by availability and cost. Many published predictive equations estimate energy and protein requirements based on different factors listed above and range from 40%-75% in accuracy compared with indirect calorimetry. A weight-based approach provides simplicity over predictive equations with calories ranging from 20-35 kcal/kg/d and protein from 0.8-2.5 g/kg/d (see Table 2 ). 5, [7] [8] [9] [10] [11] [12] Recently new approaches to macronutrient dosing have emerged and include strategies such as permissive underfeeding, hypocaloric high-protein feeding, and supplemental PN. Permissive underfeeding, used primarily in critically ill patients, provides less energy than estimated to prevent complications such as hyperglycemia and electrolyte derangements. This strategy has been associated with fewer infectious complications and reduced hospital mortality. 7, 9 Hypocaloric high-protein feeding, studied in critically ill obese patients, provides a caloric deficit with adequate protein supplementation and has been shown to be as efficacious as eucaloric feeding. This strategy may decrease hospital length of stay, multiple-organ failure, and number of hyperglycemic episodes per day. [10] [11] 13 Supplemental PN, whether early (1-7 days after intensive care 
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Macronutrients
Protein
Aiding in formation and repair of body structures such as skin, tendons, membranes, muscles, organs and bones, proteins are an important component of the human body's mass and structure. In PN, a mixture of crystalline AAs is used to provide protein and, if oxidized for energy, yields 4 kcal/g. Standard AAs are a mixture of essential and nonessential amino acids that are commercially available from a variety of manufacturers. 19 Specialized or modified AA preparations also available are specifically formulated to meet the needs of disease or specific AA requirements in adults. 20, 21 These products can be more costly with controversial clinical benefit over protein dose modification using standard AA preparations. Table 3 details a comparison of the various AA preparations available. [19] [20] [21] [22] [23] [24] While preparations are therapeutic equivalents, they are not generic equivalents due to different buffering electrolytes and pHs, which can affect compatibility.
Carbohydrates
Carbohydrates, the primary energy source in the human body, provide approximately 45%-65% of daily energy requirements. Stored as glycogen in the liver and muscle, it is a vital energy source for the brain and other cells in the body to function properly.
In PN, the carbohydrate substrate used is dextrose monohydrate. It often makes up about 60% of total kcal/d or approximately 70%-85% of nonprotein calories in the preparation. 5, 25 An acidic solution with a pH of 4.0 (3.2-6.5), dextrose provides 3.4 kcal/g and is commercially available from a variety of pharmaceutical manufacturers. 19, 20 Available only in one commercially prepared premixed peripheral PN preparation, glycerin (also called glycerol), a sugar alcohol, can alternatively be used as a carbohydrate source providing 4.3 kcal/g. This preparation has been reported to induce less hyperglycemia than dextrose-containing preparations. 19, 20 
IV Fat Emulsion
Fatty acids aid structural integrity and fluidity of cell membranes and affect cell signaling pathways such as apoptosis, inflammation, and cell-mediated immune responses. 26 Classified by hydrocarbon chain length (short, medium, long), number of double bonds (saturation), and location of those double bonds, fatty acids are a calorie-dense form of energy for the body. Providing about 15%-30% of nonprotein calories in a PN admixture, it serves as a source to prevent essential fatty acid deficiency (EFAD). 5 Using this calorie-dense macronutrient as part of a "mixed-fuel" system can reduce infusion rates and total dextrose needed in PN, improve metabolic tolerance, and prevent complications compared with fat-free PN admixtures (see Metabolic Complications of PN section).
In and not yet to the market a combination of olive oil/soybean oil (Clinolipid; Baxter International, Deerfield, IL), which are summarized in Table 4 . [27] [28] [29] [30] Ranging in concentrations from 10%-30%, these oil-in-water emulsions also contain egg phospholipids as an emulsifier and glycerin to adjust osmolality. 19, 20 Glycerin also adds caloric content to the IV fat emulsion (IVFE) and varies depending on concentration of the fat emulsion. A 10% emulsion provides 1.1 kcal/mL in 20, 26, 31 Soybean oil, a mixture of ω-6 and ω-3 polyunsaturated fatty acids, contains a larger number of double bonds, the target for lipid peroxidation, leading to an increase in oxidative stress. In addition, ω-6 is metabolized to arachidonic acid, leading to proinflammatory eicosanoids such as prostaglandins, thromboxanes, and leukotrienes. Due to these mechanisms, soybean oil-based IVFE has been associated with adverse immunological effects and proinflammatory properties. [31] [32] [33] The 2016 joint guidelines by ASPEN and the Society of Critical Care Medicine (SCCM) suggest no soybean oilbased IVFE be administered during the first week following the initiation of PN in critically ill patients and to a maximum of 100 g/wk if there is concern for EFAD due to the possibility of immunosuppression (quality of evidence: very low). 7 This recommendation is based primarily from a study by Battistella et al 34 conducted nearly 20 years ago in a small study population of 60 trauma patients. Well-designed clinical trials are needed to determine the impact on immune response and overall risk of IVFE in the critically ill patient. 7, 34, 35 Olive oil, a monounsaturated fatty acid containing ω-9 fatty acids, has one double bond and is less susceptible to lipid peroxidation than soybean oil. 26, 36 The Food and Drug Administration (FDA)-approved product in the United States is an olive oil/soybean oil-based IVFE in a 4:1 ratio (Clinolipid) but, at the time of this publication, is not yet available on the market. When studied against soybean oil-based products, it has shown less impact on neutrophil function, lymphocyte proliferation, and interleukin-2 production in vitro and in vivo as well as shorter mechanical ventilation time and ICU length of stay. [37] [38] [39] [40] In contrast, 2 studies found no difference in length of stay, mortality, nosocomial infection, or inflammatory and oxidative stress markers between patients. These studies did find an increase in systolic blood pressure and impaired endothelial function in patients receiving soybean oil compared with olive oil. 41, 42 Aforementioned studies are limited by the heterogeneity of study design, population, and specific IVFE. Mixed olive oil/soybean oil-based IVFE may be beneficial in populations where immunological and inflammatory effects may be detrimental to outcomes such as critically ill, severely burned, or immunocompromised patients.
Electrolytes
Electrolyte requirements for an adult receiving PN vary depending on anticipated patient requirements, nutrition status, presence of organ dysfunction, and underlying disease states. In addition, ongoing losses, medications, and fluid or electrolyte shifts can also necessitate electrolyte dose changes to the PN admixture. As an example, potassium, phosphate, and magnesium may need to be dosed more conservatively in renal dysfunction because of impaired excretion. 5 See Table 5 for suggested daily maintenance and maximum electrolyte PN additions for adults.
Typically to maintain acid base balance, the chloride and acetate are used in equal amounts, but adjustments can be made depending on acid base status. Often by maximizing the amount of acetate in PN, one can avoid exacerbating metabolic acidosis; conversely, maximizing chloride and limiting acetate will reduce the risk of exacerbating a metabolic alkalosis. 5, 20 Commercially available AA preparations contain certain electrolytes that need consideration such as acetate, which can affect the patient's acid base status, and phosphate, which can disrupt admixture chemical stability with calcium. 20 Electrolytes are available in various salt forms (see Table 6 ) and are manufactured as single salts or as combination products. They can also come included in certain stock AA preparations as well as commercially available PN admixtures. Certain salts are preferred for use in PN admixture because they are less likely to cause incompatibilities compared with alternative salts such as calcium chloride, calcium gluceptate, and magnesium chloride.
While there is no "one size fits all" approach to dosing electrolytes in PN, guidelines recommend that electrolytes shall be ordered as the complete salt form vs the individual ion and as amount per day or amount per kilogram per day. 44 We suggest that practitioners new to ordering electrolytes in PN develop a systematic approach to dosing like the example in Figure 1 .
Vitamins
Essential to maintain fundamental functions of the body, including growth, metabolism, and cellular integrity, vitamins are organic substances that are unable to be synthesized by the human body and necessary additions to PN. Commercially available products for use in adult PN preparations include single-vitamin products and multivitamin products with both fatsoluble and water-soluble vitamins. Parenteral fat-soluble vitamin daily dose in multivitamin products is approximately the same as the oral recommended daily allowance (RDA). Watersoluble vitamins in parenteral doses are 2.5-5 times greater than oral RDA. [45] [46] [47] [48] Rationale for the increased requirements over oral RDA includes increased needs secondary to malnutrition, presence of baseline vitamin deficiencies, and metabolic changes secondary to acute and chronic illness. Additional rationale specific to water-soluble parenteral vitamins is the increased urinary vitamin losses compared with oral administration. 48 Table 7 provides the composition of commercially available parenteral multivitamin products in the United States for adults. Experts have raised concern as to whether the daily dose of 200 International Units per day of vitamin D is adequate to avoid deficiency in a PN-dependent patient. Furthermore, there is currently no separate parenteral ergocalciferol or cholecalciferol product commercially available to supplement a patient who is vitamin D deficient and either is unable to take or fails to respond to oral vitamin D supplements. 48 
Trace Elements
Trace elements are required for normal metabolism and growth. Commonly used trace elements include copper, manganese, chromium, zinc, selenium, and iron. Trace element (TE) products are available as single-entity products and in various multiple TE combinations and concentrations. Table 8 provides the daily requirement for TEs in adults based on healthy individuals with normal losses and details the doses provided in multi-TE products.
Adult daily copper requirements for the PN patient are 0.3-0.5 mg. This is 50% less than the dose provided in standard multi-TE products. Since copper is mainly excreted in the bile, the amount provided in PN should be reduced by 0.15 mg in patients with cholestasis. 48, 49 Manganese, also mainly excreted in bile, is provided in multi-TE products in a standard daily dose of 400-800 mcg. This is 4 times the recommended parenteral requirement of 55 mcg daily. 49 Manganese has also been found as a contaminant in PN. 50 Omit copper or manganese in a patient with symptoms of toxicity or with elevated whole-blood concentrations. 49 Standard multi-TE dose of chromium ranges from 10-12 mcg, which is similar to the recommended daily dose of 10 mcg. Consider an omission or reduction of PN chromium dose in patients with renal failure or elevated serum creatinine due to risk of accumulation. 49 The typical dose of zinc provided in PN of 3-5 mg/d is adequate to meet estimated adult parenteral requirements. 48, 49 Zinc has also been found as a contaminant in PN at approximately 1.1 mg/2L. 50 Selenium in a dose of 60 mcg is provided in multi-TE products and meets minimal adult recommended requirements. Higher doses may be required to maintain ideal serum concentrations as selenium needs are increased in patients with malnutrition, critical illness, and burn injuries. 48, 49 Other TEs that can be supplemented in PN are molybdenum, iodine, and iron. The most common of these is iron. There are several injectable iron product available on the market, but only iron dextran is approved for addition to PN and should be reserved for addition in IVFE free admixtures secondary to the potential to destabilize an admixture containing IVFE. 31, 51 (See Parenteral Nutrient Systems for Delivery section.)
PN Drug Shortage Considerations
In recent years, a multitude of drug shortages in the United States have affected PN compounding. Nearly all components of PN have been in short supply at times over the past 5 years due to a variety of factors, including acquisition of raw materials, manufacturing interruptions, and consolidation of the market. ASPEN has assembled a panel of experts to establish management strategies for shortage situations. Please visit ASPEN Latest News and ASPEN Product Shortage Latest News (http://www.nutritioncare.org) for additional information on product shortages and considerations to assist in management of specific shortage issues. These recommendations are not to be used during routine clinical practice when ample supply is available. Traditional recommended dosing of PN components should resume after resolution of product shortage. 53, 55 For patients in whom partial goal feeds are desired on day 1, strategies are outlined in Table 9 for safe initiation, which include limiting initial maximum carbohydrate dose. In most adult patients, goals can be achieved in 2-3 days, and advancement is often based on glycemic control, electrolyte management, and IVFE tolerance. 5, 25, 53 Monitoring of PN should include routine evaluation and assessment of clinical condition with the focus on nutrition and metabolic effects of the PN therapy. Serial documentation is helpful to guide adjustments to fluids, electrolytes, and nutrient therapy. 54 See Table 10 for suggested monitoring parameters and frequency. 25, 53, 54, 56, 57 The goal of PN therapy is to return to using the gastrointestinal (GI) tract with oral diet or enteral feeds when possible. Transitional feeding is considered the period between oral diet or enteral nutrition initiation and PN discontinuation. This transition should be planned to avoid potential decline in nutrition status when PN is discontinued. Figure 2 details a suggested approach for transition and discontinuation of PN. For many patients PN may be discontinued as soon as they are able to tolerate a diet that has been advanced past clear liquids. Others may require a more detailed transitional feeding plan. Individuals with significant nutrition compromise such as those with malabsorption syndromes, those with active malignancy, the elderly, and those who are debilitated or require special monitoring are candidates for this more detailed plan.
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Metabolic Complications of PN
Hyperglycemia
Hyperglycemia is a common complication of PN therapy. Often multifactorial, risk increases with age, obesity, severity of illness, rate of dextrose infusion, and diabetes mellitus diagnosis. Studies have shown development of PN-associated hyperglycemia independently increases odds of complications during hospitalization and mortality. 58, 59 A multicenter study of 605 non-critically ill patients receiving PN demonstrated patients with mean blood glucose levels >180 mg/dL were 5.6 times more likely to die while hospitalized compared with those with mean blood glucose levels <140 mg/ dL. 60 These observations indicate that prevention and correction of hyperglycemia via modification of nutrient composition, use of insulin therapy, or a combination of both should be strongly considered during PN therapy. Strategies to prevent and manage hyperglycemic excursions include limiting dextrose infusions at rates ≤4 mg/kg/min or 6 g/kg/d. It is also recommended in diabetes mellitus and critically ill patients to limit, at least initially, dextrose infusions to 2 mg/kg/min or 150 g/d until control of serum glucose is attained. After serum glucose control is achieved (140-180 mg/dL), rates of dextrose infusion can be increased to provide nutrition needs. 55, 58 Insulin is the treatment of choice to control hyperglycemia during PN with subcutaneous and IV insulin being effective in management. Treatment with IV continuous insulin infusion is preferred in patients with conditions such as critical illness, hemodynamic compromise, or multifactorial hyperglycemia as it allows for frequent dose adjustments. Another option is directly adding insulin to the PN preparation. It is important to note that regular insulin is the only insulin compatible with PN preparations. Studies have generally used insulin-to-carbohydrate ratios to determine the initial dose. Ratios range from 1 unit per 4 g to 1 unit per 15 g in patients , bicarbonate or total carbon dioxide; INR, international normalized ratio; K, potassium; Na, sodium; PT, prothrombin time. with diabetes mellitus and up to 1 unit per 20 g in patients with no diagnosis of diabetes mellitus, with titration as needed.
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Hypoglycemia
Hypoglycemia with PN is typically seen in the following situations: endogenous insulin levels not adjusting to abrupt withdrawal of dextrose, recovery from acute illness, decreased dose of corticosteroids or vasopressors, progressive organ dysfunction, or insulin overdose in the PN preparation. It has been associated with increased risk of complications, length of hospitalization, and mortality. 53, 59 Treatment includes initiation of dextrose infusion at a similar rate as the PN admixture (keeping in mind typical PN solution contains 10%-20% dextrose), administration of 12.5-25 g of a 50% dextrose, and stopping any source of insulin administration. 59 Patients at higher risk for rebound hypoglycemia are those with diabetes mellitus, treatment with IV insulin, and lower BMI. 64 Strategies for reducing this rebound hypoglycemia include gradual taper of PN infusion rate over 1-2 hours before discontinuation and establishing oral diet or enteral nutrition (EN) tolerance prior to PN discontinuation. 65, 66 EFAD Essential fatty acids, or those that cannot be synthesized by the body, include linoleic acid (an ω-6 fatty acid) and α-linolenic acid (an ω-3 fatty acid). These are further converted in the body to arachidonic acid and eicosapentaenoic acid, both essential for second-messenger formation in the body. 67 Clinical signs and symptoms of deficiency include scaly dermatitis, hair loss, anemia, thrombocytopenia, hepatomegaly, and fatty liver. [68] [69] [70] Biochemical evidence of EFAD can be determined by a triene/tetraene ratio of >0.4 representing decreased linoleic acid levels, which can occur within 1-3 weeks in adults receiving IVFE-free PN. 67 To prevent EFAD, it is recommended to provide at least 2%-4% of linoleic acid and 0.25%-0.5% of α-linolenic acid of total daily calories. In practice, providing approximately 5% of total weekly calories or about 100 g/wk as soybean-based IVFE usually is sufficient for most adult patients. 5 
Hypertriglyceridemia
Hypertriglyceridemia occurs if the infusion rate of IVFE exceeds the capacity of plasma fat clearance. Reported complication occur 6%-38% of the time in patients receiving PN. Dose used as well as population factors are known to increase risk of intolerance during PN therapy. These risk factors include renal failure, sepsis, pancreatitis, dextrose overfeeding or hyperglycemia, diabetes mellitus, obesity, alcoholism, and multiple-organ failure. Drugs such as corticosteroids, cyclosporine, tacrolimus, clevidipine, propofol, and rapid infusion of IVFE (>0.11 g/ kg/h) may also put patient at risk for intolerances. 71, 72 Hypertriglyceridemia secondary to PN therapy can impair immune response, increase the risk of pancreatitis, and alter pulmonary hemodynamics. 71, 73 Serum triglyceride concentration should be monitored in a patient receiving PN or IVFE with acceptable levels <400 mg/dL. 5 Other factors affecting plasma clearance of IVFE include free phospholipid content and particle size. Amount of phospholipid, as described in percentage, is similar between all concentrations of IVFE. Clearance of the 20% concentration is faster than that of the 10% concentration due to its lower concentration of free phospholipids (those not participating as an emulsifying agent) and its larger particle size. 71 Strategies to reduce hypertriglyceridemia during PN therapy include temporary discontinuation, reducing the infusion rate, and limiting provision to provide only essential fatty acids.
Refeeding Syndrome
Refeeding syndrome is generally described as the metabolic and physiologic shift in fluid and electrolytes after introduction of nutrition in malnourished patients and can occur with oral nutrition, EN, or PN. 74 Carbohydrate introduction stimulates insulin secretion, causing minerals and electrolytes to shift intracellularly. This shift can lead to decreased serum phosphorus, magnesium, and potassium levels as total body stores are depleted. Furthermore, to maintain osmotic neutrality within the plasma, the body retains sodium and water, which can lead to development of fluid overload and its clinical consequences (congestive heart failure, pulmonary edema, and arrhythmias), especially in critically ill patients. 74, 75 Vitamin and mineral deficiencies can also be observed in refeeding syndrome. In particular, thiamin, a cofactor for glycolysis, can quickly become depleted with weight loss and malnutrition. Thiamin deficiency in a malnourished patient has led to Wernicke encephalopathy in patients given PN with high carbohydrate loads. 74, 76 Prevention, treatment, and monitoring of refeeding syndrome should include identifying at-risk patients and conservative carbohydrate initiation and advancement. Examples of patients with risk for refeeding syndrome are those with anorexia nervosa, history of excessive alcohol consumption, and those with chronic disease states causing undernutrition (cancer, chronic obstructive pulmonary disease, malabsorption syndromes). 74 Special attention should be paid to correction of critical electrolytes prior to the initiation of nutrition and concomitantly with the nutrition therapies. 74 In addition to the daily requirements provided by IV multivitamin preparations, additional supplementation with 50-100 mg/d of thiamin for 5-10 days should be provided to patients at risk for thiamin deficiency or refeeding syndrome. The significance of other vitamin deficiencies is less clear in refeeding syndrome, but administering other supplemental vitamins when deficiency is suspected may also be warranted.
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PN-Associated Liver Disease
PN-associated liver disease (PNALD) encompasses a multitude of conditions, including cholestasis (decrease in bile flow), cholelithiasis (gallstones), and hepatic steatosis (fat accumulation in the liver). 77 Mild elevations of transaminases and alkaline phosphatase concentration usually occur 2 weeks after PN is initiated. These mild elevations may return to normal while the patient is still receiving PN but almost always normalize when PN is discontinued. Adults may develop complications of steatosis and steatohepatitis, which are generally asymptomatic and rarely result in permanent liver damage. 78 The complication of PN-associated cholestatic syndrome is seen more frequently in the pediatric population than in adults. Both age groups will have complications of biliary sludge and cholelithiasis. 77 Diagnostic features include increases in biochemical markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB), direct bilirubin (DB), and alkaline phosphatase. Total bilirubin increase >2 mg/dL is considered reflective of cholestasis. 77 Although limited data exist, PN has been linked to the development of PNALD. Excess energy intake in any form, as well as dextrose rates >4-5 mg/kg/min, results in increased insulin levels and lipogenesis. This can lead to fat deposition in the liver and steatosis. 79 Limiting dextrose infusion rates and avoidance of overfeeding reduce the risk of hepatic steatosis. 78 Dose and IVFE composition has been associated with the development of PNALD. Soybean oil-based IVFE contains high concentrations of phytosterols and ω-6 fatty acids. Phytosterols may produce biliary sludge and stones as they are not metabolized effectively by the liver. 80 It has been postulated that both the phytosterol content along with ω-6 content of soybased IVFE contribute to hepatic disease seen in long-term PN patients. 81 Cholestasis and PNALD have been associated with excessive IVFE doses. Following recommended dosing limits for adults with available products can help prevent PNALD. 82 Other strategies to manage and prevent PNALD include ruling out other causes of liver damage (ie, hepatotoxic medications or supplements, infectious hepatitis, sepsis), increasing enteral intake, and cycling PN. Loss of enteral intake decreases cholecystokinin, the regulatory hormone responsible for stimulating gallbladder contractions, and leads to cholestasis and cholelithasis. 78 Not using the enteral route has also been associated with mucosal atrophy and decreased immunity, causing overgrowth of hepatotoxin-producing anaerobic intestinal bacteria. Introducing EN early is the best method to prevent this complication, but other methods, including using ursodeoxycholic acid and exogenous cholecystokinin, as well as treating small bowel bacterial overgrowth, have been proposed. 79, 82 Cycling PN (infusing PN over 10-16 hours) has limited evidence to support its use in PNALD but has historically been thought to decrease both incidence and severity of disease by reducing prolonged hyperinsulinemia. 77 
Metabolic Bone Disease
Metabolic bone disease (MBD) represents a range of bone problems from osteopenia and osteomalacia to overt osteoporosis. Often multifactorial, this bone loss is associated with many medical conditions (diabetes mellitus, liver cirrhosis, sclerosing cholangitis, hyperthyroidism, hyperparathyroidism, pancreatic insufficiency, short bowel syndrome, Crohn's disease, and postgastrectomy syndrome) as well as immobilization. [83] [84] [85] Medications can also contribute to MBD, with commonly implicated ones including corticosteroids, anticonvulsants, heparin, antiretrovirals, warfarin, and overreplacement of levothyroxine. Aluminum contamination in PN and tobacco and alcohol use have also been associated with increased risk of MBD development. 85, 86 Exact prevalence of PN-associated MBD is unknown, and it is unclear if PN accelerates or causes bone loss as most patients receiving long-term PN have at least one other risk factor.
Symptoms of MBD range from asymptomatic to bone pain, limited mobility, and fractures. Chemical markers for disease include hypercalcemia or hypocalcemia, low to normal parathyroid hormone (PTH) level, elevated urine calcium, and increased alkaline phosphatase. 84, 85 Numerous elements of PN nutrient composition have been postulated to affect bone metabolism. Therefore, careful PN admixture design for the long-term PN patient is important to minimize risk. It is known that to maintain optimal bone health, adequate amounts of protein, energy, calcium, phosphorus, magnesium, and vitamins D and K are necessary. Less understood is the effect of providing these and other nutrients intravenously on bone density. Several components of PN have been shown to either affect urinary calcium excretion or alter bone metabolism. Table 11 lists PN components thought to be factors associated with MBD as well as suggested admixture modifications. Identifying these factors and preparing PN admixture accordingly can improve bone mineralization and reduce risk for development of MBD in patients receiving PN. Patients at risk or with osteoporosis should be counseled on lifestyle modification such as smoking cessation, reduction of caffeine intake, and limiting alcohol consumption. It is reasonable for long-term PN patients to receive bone density measurements at baseline and annually.
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Parenteral Nutrient Systems for Delivery
Admixtures (2-in-1 vs Total Nutrient Admixture)
Often called a 2-in-1 PN, this formulation is a mixture of dextrose and AAs in which electrolytes, vitamins, and trace elements are added and IVFE may be infused separately. A total nutrient admixture (TNA), also known as a 3-in-1, is an admixture that contains IVFE as well as components of PN provided in a 2-in-1 admixture in a single container.
Many organizations and home care providers have elected to transition to the TNA system for convenience and cost advantages. These advantages are significant but must be evaluated against the disadvantages. Following is a brief discussion of the pros and cons summarized in Figure 3 . 20, [88] [89] [90] [91] [92] [93] [94] [95] As PN components were developed and refined, the practice standards as well as systems for delivery also evolved. Traditionally, 2-in-1 systems with separate IVFE infusions have been the standard infusion practice. In an effort to simplify administration procedures and diminish potential for microorganism growth, the approach of adding the IVFE directly to the admixture, providing one large container for daily infusion, was developed and researched. IVFE preparations do not contain preservatives and thus can support the growth of gram-positive and gram-negative bacteria and fungi. 94, 95 Furthermore in 2002, the Centers for Disease Control and Prevention put forth guidelines limiting the hang times of single-container IVFE infused alone to 12 hours maximum. 96 When combining IVFE with AAs and dextrose, the microbial growth is inhibited, allowing for the TNA that includes IVFE to hang for 24 hours. 97, 98 Because IVFE particle size is larger, a 1.2-micron air-eliminating filter for TNA is recommended. This is in contrast to 2-in-1 admixtures, which contain particulates of smaller size, allowing the use of a 0.22-micron air-eliminating filter. 51, 99 Administration sets and filters on all PN should be changed with each new PN container or every 24 hours due to possibility for contamination of the filter. 44, 96 Stability and compatibility of ingredients should be considered when comparing delivery systems. IVFEs are most stable at a manufactured pH of 8, and adding IVFE to an acidic admixture of dextrose and AAs increases the risk for "cracking," or separation of fat droplets from emulsion. 51 ,100 IVFE can also be destabilized by higher concentrations of monovalent (Na ) are highly disruptive and should not be added to a TNA. The opaque nature of a TNA makes visualization of particulates or precipitates such as calcium phosphate impossible. 51 These complications can be prevented by following safe practice guidelines. 5, 44, 51 Several aspects of safe PN practice include standardizing prescribing and ordering processes as well as using technology to aid the practitioner in identifying possible unstable or incompatible preparations. Due to the complexity of PN preparations, it is vital for a pharmacist to review and verify all PN orders as well as healthcare facilities to standardize labeling, compounding, and administration procedures. 44 
Multichamber Bags vs Compounded
Multichamber bags (MCBs) and pharmacy-compounded PNs are the available modalities for PN. When considering which system to use at your institution, one should evaluate safety, efficacy, and cost. Until recently, only dual-chamber products containing AAs and dextrose were available in the United States. On August 25, 2014, the FDA approved indications for use of triple-chamber bags containing AAs, dextrose, and IVFE in a single bag. The macronutrient components are separated by an internal membrane meant to be broken and mixed prior to administration. To date, there are no randomized controlled studies comparing dualchamber with triple-chamber bags. Potential advantages and disadvantages to choosing an MCB compared with compounding a PN are reviewed in Figure 4 . 44, [101] [102] [103] [104] [105] [106] The MCB fixed combinations available in the United States are summarized in Table 12 . [107] [108] [109] Safety. The safety profile of MCBs has been shown to be superior to that of compounded products due to fewer preparation steps (minimizing compounding mistakes) and less contamination from product manipulation. 101, 105, 106, [110] [111] [112] Turpin et al 105, 111 showed fewer adverse events related to infections and a 30% decrease in the probability of developing a bloodstream infection with MCBs compared with compounded products. A study completed in South America found an increased rate of bloodstream infections with TNA-compounded products compared with TNA MCBs. While this study aligns with other literature, it is difficult to generalize the results because the IVFE used (olive oil and MCT/LCT combination) is not available in the United States. 88 Efficacy. Literature is lacking when comparing MCBs to compounded PN for efficacy. Several studies have shown standardized PN preparations are as effective as compounded in controlling serum electrolytes in both adults and pediatrics. [113] [114] [115] One small study done by Pounds et al 101 comparing dual-chamber bags and compounded product found no difference in normal, abnormal, high, and low laboratory values or a difference in ICU length of stay or length of PN therapy, suggesting that dual-chamber bags are as efficacious as compounded products.
Cost. Several studies have shown MCBs to be less costly compared with compounded products. 101, 105, 116 Each study evaluated different aspects of cost associated with PN, making interpretation of data difficult. Turpin et al 105 showed an average acquisition cost for MCBs of $164 compared with $239 for a compounded PN admixture. Pounds et al 101 showed that a 1-year charge for ingredients in an MCB preparation was $242,178 compared with $284,112 for the charge of ingredients in a compounded product, estimating around a $40,000 cost savings per year when using MCBs. However, this study did not evaluate personnel cost associated with compounding a PN and should be interpreted with caution. Pichard et al 116 found MCBs to be more cost-effective than compounded PN due to reduction of labor cost and pharmacy overhead cost. This study was done in Switzerland, making comparison to other countries' salaries and cost of PN product difficult. Based on the available literature comparing MCBs with compounded PN, MCBs may be a safer product with similar efficacy and might be a cost-effective option for some institutions. More well-designed studies are needed to fully assess safety, efficacy, and cost in all patient populations.
Conclusion
The nutrition support clinician has the essential task of creating a safe and effective PN for the wide variety of patients who are otherwise unable to be fed enterally. PNs are complex prescriptions that require appropriate indications for use, route of administration, initiation, and monitoring parameters as well as accurate admixture design. Being familiar with new methods for feeding, therapy options, and systems of delivery empowers clinicians to create and manipulate admixture design to prevent the vast array of complications that can arise with PN. It is an exciting time for nutrition support, with new products coming to market and new curricula for PN competencies. This article provides the foundation for PN admixtures and nutrition support to help provide the safest and most effective PN in the adult patient.
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